Pharmaceuticals, Biotechnology & Life Sciences

Phase‑3 data for Bayer’s Asundexian shows a 28 % stroke risk reduction and 31 % fewer major bleeds vs warfarin, boosting share price and promising a safer oral anticoagulant for atrial fibrillation patients.

Discover how Mettler‑Toledo’s precision weighing instruments keep labs compliant, accurate, and profitable—no new corporate moves, just steady innovation and growth.

Grifols SA’s modest share‑price rebound signals steady earnings and strategic growth, with new Egyptian plasma‑collection moves and targeted M&A poised to boost margins and counter patent cliffs in a $15 bn market.

Imfinzi’s FDA approval for peri‑operative gastric cancer marks a breakthrough, pairing powerful immunotherapy with FLOT chemotherapy to cut progression risk by 28% and boosting AstraZeneca’s market and patient‑care impact.

AbbVie’s Skyrizi gets Canada’s public drug plan approval, boosting ulcerative colitis access and revenue prospects for the specialty pharma leader.

Read how Bayer’s FDA approval of a new lung‑cancer therapy is driving share gains and reshaping NSCLC treatment prospects.

Lonza Group AG: solid margins, growing CMS revenue, and a proactive stance on digital, regulatory and sustainability trends that could drive a multi‑year upside.

Galderma Group AG’s modest share rise on 26 Nov shows strong biotech fundamentals, rising consumer confidence and a supportive SMI rally, highlighting its growth prospects and resilient pipeline.

Discover how Eis Co.’s subcutaneous Leqembi (lecanemab) filings in Japan & the U.S. aim to accelerate Alzheimer’s therapy access, boost market share, and secure IP protection.

WuXi AppTec’s recent Hong Kong share dip reflects broader market swings, yet deeper analysis shows regulatory tightening, margin pressure, and a strategic pivot into biologics that could drive future growth.